Skip to main navigation

About Us
- Leadership
- Board of Directors
Science
- About CNM-Au8®
Pipeline
Patients
- EAP
Investors
Contact

About Us
- Leadership
- Board of Directors
Science
- About CNM-Au8®
Pipeline
Patients
- EAP
Investors
Contact

Scientific Posters & Presentations

Year

Presentation of VISIONARY-MS Long Term Extension Results at 2024 AAN Annual Meeting

Apr 16, 2024

Supporting Materials

AAN 2024 – VISIONARY-MS LTE Presentation 3.7 MB

AAN 2024 – VISIONARY-MS LTE Poster 4.3 MB

Presentation of VISIONARY-MS Long-Term Extension Results at ACTRIMS Forum 2024

Feb 29, 2024

Supporting Materials

VS-MS ACTRIMS 2024 6.1 MB

Survival Analyses of Clene Expanded Access Programs in ALS

Feb 22, 2024

Supporting Materials

Survival Analyses of Clene Expanded Access Programs in ALS 6 MB

Clinical Trials Update at 2024 International Alliance of ALS/MND Associations

Jan 25, 2024

Supporting Materials

Clinical Trials Update at 2024 International Alliance of ALS/MND Associations 2.5 MB

Presentation of VISIONARY-MS Trial Results by Michael Barnett, MBBS PhD FRACP FRCP, at the 2023 AAN Annual Meeting

Apr 25, 2023

Supporting Materials

AAN 2023 – VISIONARY-MS 9.1 MB

Evidence for Survival Benefit in ALS with CNM-Au8 Treatment Across Three Study Populations, 2023 AAN Annual Meeting

Apr 25, 2023

Supporting Materials

AAN 2023 – CNM-Au8 Survival Benefit 5.8 MB

Clene Inc. Presentation of VISIONARY-MS Trial Results at ACTRIMS Forum 2023

Feb 23, 2023

Supporting Materials

VS-MS ACTRIMS 2023 8.6 MB

Presentation of VISIONARY-MS Trial Results by Michael Barnett, MBBS PhD FRACP FRCP, at PACTRIMS 2022

Nov 25, 2022

Supporting Materials

PACTRIMS Visionary - MS 4.4 MB

Clene Inc. Presentation of CNM-Au8 Topline Data From the HEALEY ALS Platform Trial

Oct 3, 2022

Clene Inc. Presentation of RESCUE-ALS Trial Results at 2022 AANEM Annual Meeting

Sep 21, 2022

Supporting Materials

RESCUE-ALS Poster - Encore 1.9 MB

Clene Inc. Presentation of Updated Interim Data from RESCUE-ALS Open Label Extension Study at 2022 AANEM Annual Meeting

Sep 21, 2022

Supporting Materials

RESCUE-ALS OLE Poster - Survival 1.4 MB

Clene Inc. – Phase 2 VISIONARY-MS Trial Results

Aug 15, 2022

Clene Inc. Presentation of RESCUE-ALS Trial Results at 2022 ENCALS Meeting

Jun 1, 2022

Supporting Materials

RESCUE-ALS Poster - Encore 5.7 MB

RESCUE-ALS Poster - Biomarker Findings 6.8 MB

Clene Inc. Presentation of Updated Interim Data from RESCUE-ALS Open Label Extension Study at 2022 ENCALS Meeting

Jun 1, 2022

Supporting Materials

RESCUE-ALS Poster - Survival 3.5 MB

RESCUE-ALS Poster - Quality of Life 3.9 MB

Clene Inc. Presentation of Preclinical Evidence for Neuroprotection by CNM-Au8 in Multiple in vitro Models of ALS at 2022 ENCALS Meeting

Jun 1, 2022

Supporting Materials

Preclinical ALS Poster 5.9 MB

Clene Inc. Presentation of Updated Interim Data from RESCUE-ALS Open-Label Extension Study at 2022 AAN Annual Meeting

Apr 5, 2022

Supporting Materials

Presentation 4.5 MB

RESCUE-ALS Trial Results: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CNM-Au8 to Slow Disease Progression in ALS (MDA Clinical & Scientific Conference 2022)

Mar 14, 2022

Supporting Materials

RESCUE-ALS Poster 5.7 MB

RESCUE-ALS Oral Presentation 5.6 MB

CNM-Au8 Gold Nanocatalysis Protects Neurons Against Degeneration and Death in Multiple in vitro Models of Amyotrophic Lateral Sclerosis (MDA Clinical & Scientific Conference 2022)

Mar 14, 2022

Supporting Materials

Preclinical ALS Poster 22.7 MB

Evidence for an ALS Survival Benefit with CNM-Au8 Treatment: Interim Results from the RESCUE-ALS Trial Long-Term Open Label Extension (MDA Clinical & Scientific Conference 2022)

Mar 14, 2022

Supporting Materials

RESCUE-ALS Open Label Extension Poster 26.7 MB

Evidence for Brain Energy Metabolic Support with CNM-Au8 Treatment: Results from the REPAIR Phase 2 Clinical Trials (MDA Clinical & Scientific Conference 2022)

Mar 14, 2022

Supporting Materials

REPAIR Poster 4.9 MB

Improvement of Brain Energy Metabolism in Relapsing MS: Results from Phase 2 REPAIR-MS Clinical Trial With CNM-Au8 at ACTRIMS Forum 2022

Feb 24, 2022

Supporting Materials

REPAIR-MS Poster 3.2 MB

VISIONARY-MS Blinded Interim Data Update at ACTRIMS Forum 2022

Feb 24, 2022

Supporting Materials

VISIONARY-MS Poster 2.9 MB

Clene Inc. Late-Breaking Presentation of RESCUE-ALS Clinical Trial Results at the 32nd International Symposium on ALS/MND

Dec 10, 2021

Supporting Materials

Presentation 4.9 MB

Clene Inc. Poster Presentation of RESCUE-ALS Clinical Trial Results at the 32nd International Symposium on ALS/MND

Dec 7, 2021

Supporting Materials

RESCUE-ALS Poster 8.5 MB

Clene Inc. Presentation of Updated Data from RESCUE-ALS Clinical Trial at the Annual ALS ONE Research Symposium

Nov 30, 2021

Supporting Materials

Presentation 13.2 MB

Clene Inc. Presentation of RESCUE-ALS Topline Clinical Trial Results

Nov 2, 2021

Supporting Materials

Presentation 23.4 MB

Updated Blinded Interim Phase 2 Data from VISIONARY-MS at ECTRIMS 2021

Oct 14, 2021

Supporting Materials

VISIONARY-MS Poster 2.7 MB

Results from Phase 2 REPAIR-MS Clinical Trial at ECTRIMS 2021

Oct 14, 2021

Supporting Materials

REPAIR-MS Presentation 23.4 MB

Clene Inc. Presentation at the MDS Virtual Congress 2021: Homeostatic Improvement of Brain Bioenergetic Metabolism in Parkinson’s Disease: Results From A Phase 2 REPAIR-PD Clinical Trial With CNM-Au8

Sep 17, 2021

Supporting Materials

Presentation 2.3 MB

Video Presentation

Blinded Interim Update on RESCUE-ALS: A Randomized, Placebo-Controlled, Phase 2 Study at ENCALS 2021

May 12, 2021

Audio Presentation

Supporting Materials

Presentation 7.7 MB

Updated Blinded Interim Phase 2 Data from VISIONARY-MS at the 2021 ACTRIMS Forum

Feb 25, 2021

Supporting Materials

Presentation 14 MB

Updated Interim Phase 2 Data from REPAIR-MS at the 2021 ACTRIMS Forum

Feb 25, 2021

Supporting Materials

Presentation 7.9 MB

Blinded Interim Results from RESCUE-ALS Phase 2 Study at the 31st International Symposium on ALS/MND

Nov 11, 2020

Supporting Materials

View the Abstract 6.4 MB

Presentation 792.8 KB

1-801-676-9695
info@CleneNanomedicine.com
@CleneNano

Headquarters and Development

6550 South Millrock Drive, Suite G50
Salt Lake City, Utah 84121

Manufacturing, R&D

500 Principio Parkway West Suite 400
North East, Maryland 21901

Clene Nanomedicine, Inc. is a wholly owned subsidiary of Clene Inc. | © 2024 Clene Nanomedicine, Inc. - All rights reserved